- 同花顺特色产品
- 〈高级诊股〉 全方位深度分析，提供明确投资建议
- 短期趋势：
弱势下跌过程中，可逢高卖出，暂不考虑买进。
- 中期趋势：
下跌有所减缓，仍应保持谨慎。
- 长期趋势：
已有5家主力机构披露2025-12-31报告期持股数据，持仓量总计34.23万股，占流通A股0.04%
- 波段诊断：
-
技术面诊股
诊断结果：4.0技术面打败了14%的股票
技术面评分前10的股票
近期的平均成本为42.53元。空头行情中，目前反弹趋势有所减缓，投资者可适当关注。
平均成本
近期的平均成本为42.53元。
[{"text":"\u5e73\u5747\u6210\u672c","value":"42.53","date":1772525615,"color":"0x9f0ba1"}]
市场表现
过去10个交易日，该股走势明显跑输大盘，跑输行业平均水平。
[{"date":"2026.03.04","stock":"-5.88","trade":"-0.71","ind":"-0.75"},{"date":"2026.03.03","stock":"-1.09","trade":"-2.60","ind":"-3.07"},{"date":"2026.03.02","stock":"-3.52","trade":"-2.57","ind":"-0.20"},{"date":"2026.02.27","stock":"-1.27","trade":"0.44","ind":"-0.06"},{"date":"2026.02.26","stock":"1.33","trade":"-0.81","ind":"0.19"},{"date":"2026.02.25","stock":"8.87","trade":"0.87","ind":"1.29"},{"date":"2026.02.24","stock":"-0.79","trade":"0.55","ind":"1.36"},{"date":"2026.02.13","stock":"-0.74","trade":"-0.79","ind":"-1.28"},{"date":"2026.02.12","stock":"-6.11","trade":"-1.10","ind":"0.86"},{"date":"2026.02.11","stock":"-3.10","trade":"-0.46","ind":"-0.35"},{"date":"2026.02.10","stock":"1.16","trade":"0.52","ind":"0.02"},{"date":"2026.02.09","stock":"1.29","trade":"0.67","ind":"2.17"},{"date":"2026.02.06","stock":"1.19","trade":"0.56","ind":"-0.33"},{"date":"2026.02.05","stock":"-5.20","trade":"0.23","ind":"-1.44"},{"date":"2026.02.04","stock":"-3.09","trade":"0.76","ind":"0.21"},{"date":"2026.02.03","stock":"3.29","trade":"1.56","ind":"2.19"},{"date":"2026.02.02","stock":"-12.29","trade":"-2.55","ind":"-2.69"},{"date":"2026.01.30","stock":"5.28","trade":"-0.63","ind":"-0.66"},{"date":"2026.01.29","stock":"-4.52","trade":"-0.82","ind":"-0.30"},{"date":"2026.01.28","stock":"0.15","trade":"-1.60","ind":"0.09"},{"date":"2026.01.27","stock":"0.42","trade":"-1.34","ind":"0.09"}]
常山药业,深证成指,化学制药指数
压力支撑
该股压力位为42.49元，支撑位为40.53元。
[{"text":"\u538b\u529b\u4f4d","value":"42.49","date":1772553600,"color":"0x9f0ba1"},{"text":"\u652f\u6491\u4f4d","value":"40.53","date":1772553600,"color":"0x0b52a1"}]
多空趋势
空头行情中，目前反弹趋势有所减缓，投资者可适当关注。
macd
kdj
boll
asi
bias
rsi
wr
vr
资金面诊股
诊断结果：1.6资金面打败了5%的股票
主力控盘前10的股票
行业资金
化学制药行业， 近5日资金流出较多，不建议投资者关注该行业的个股。
更新时间：03月05日 08:08
| 机构今日流向(万元) | -238.26 | 机构5日流向(万元) | -8851.38 |
| 机构10日流向(万元) | -12958.36 | 机构20日流向(万元) | -19400.81 |
机构持仓
2025-12-31 与 2025-06-30 相比，主力机构持仓量减少4292.53万股，其中基金数没有增加，主力净减仓48家，请投资者中长期谨慎为宜。
截止2025-12-31，共5家主力机构（基金5家），持仓量总计34.23万股，占流通A股0.04%
其中，基金持仓与2025-06-30相比：
增仓：1家 ，增持 5.38万股
减仓：1家 ，减持 0.17万股
新出现在主力名单中：3家 ，持有25.34万股
从主力名单中消失：51家 ，原持有4323.08万股
其中，基金持仓与2025-06-30相比：
增仓：1家 ，增持 5.38万股
减仓：1家 ，减持 0.17万股
新出现在主力名单中：3家 ，持有25.34万股
从主力名单中消失：51家 ，原持有4323.08万股
消息面诊股
诊断结果：2.5消息面打败了3%的股票
今日有利好新闻的公司
近期该股利空消息较多，投资时需谨慎。
更多>>个股资讯
- 常山药业（截止2026年2月27日）股东人数为47
2026-03-02 - 常山药业：艾本那肽上市审评处于正常流程中，未出现异
2026-03-02 - 常山药业：公司目前没有司美格鲁肽商业化开发的计划
2026-03-02 - 常山药业：2月27日获融资买入7903.72万元
2026-03-02 - 常山药业：2月26日获融资买入7674.34万元
2026-02-27 - 常山药业：二级市场股价波动受多种因素影响
2026-02-26 - 常山药业：公司正在开展依诺肝素钠注射液在美国市场的
2026-02-26 - 常山药业（截止2026年2月13日）股东人数为45
2026-02-26 - 常山药业：CSCJC3456片临床试验仍在进行中
2026-02-26 - 国产大模型进入密集发布期，创业板ETF易方达涨1.
2026-02-25
消息列表
| 重大利空 | 业绩预告 | 预计续亏 | 2026-01-30 |
| 一般消息 | 高管变动 | 个人原因 | 2025-12-12 |
| 一般消息 | 高管变动 | 取消监事会 | 2025-12-01 |
| 一般消息 | 资产重组 | 公司股权转让 | 2025-11-22 |
| 一般消息 | 股东大会 | 临时股东大会 | 2025-11-15 |
| 一般消息 | 重大事项 | 公司股东股份解押 | 2025-10-10 |
| 一般消息 | 分红转增 | 不分配不转增 | 2025-08-23 |
| 一般消息 | 重大事项 | 公司股东股份解押 | 2025-05-27 |
| 一般消息 | 分红转增 | 不分配不转增 | 2025-04-29 |
一年消息统计
| 所有消息 | 重大消息 | 非重大消息 | |
| 利好 | 0条 | 0条 | 0条 |
| 利空 | 1条 | 1条 | 0条 |
行业面诊股
诊断结果：5.0行业面打败了73%的股票
化学制药行业最新资金流向
近10日来该行业走势总体向下，明显跑输大盘。最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
行业走势
近10日来该行业走势总体向下，明显跑输大盘。
[{"date":"2026.03.04","price":"-0.75","value":"-0.71"},{"date":"2026.03.03","price":"-3.07","value":"-2.60"},{"date":"2026.03.02","price":"-0.20","value":"-2.57"},{"date":"2026.02.27","price":"-0.06","value":"0.44"},{"date":"2026.02.26","price":"0.19","value":"-0.81"},{"date":"2026.02.25","price":"1.29","value":"0.87"},{"date":"2026.02.24","price":"1.36","value":"0.55"},{"date":"2026.02.13","price":"-1.28","value":"-0.79"},{"date":"2026.02.12","price":"0.86","value":"-1.10"},{"date":"2026.02.11","price":"-0.35","value":"-0.46"},{"date":"2026.02.10","price":"0.02","value":"0.52"},{"date":"2026.02.09","price":"2.17","value":"0.67"},{"date":"2026.02.06","price":"-0.33","value":"0.56"},{"date":"2026.02.05","price":"-1.44","value":"0.23"},{"date":"2026.02.04","price":"0.21","value":"0.76"},{"date":"2026.02.03","price":"2.19","value":"1.56"},{"date":"2026.02.02","price":"-2.69","value":"-2.55"},{"date":"2026.01.30","price":"-0.66","value":"-0.63"},{"date":"2026.01.29","price":"-0.30","value":"-0.82"},{"date":"2026.01.28","price":"0.09","value":"-1.60"},{"date":"2026.01.27","price":"0.09","value":"-1.34"}]
深证成指,化学制药行业
行业排名
| 排名 | 股票名称 | 1月涨跌幅 | 5日涨跌幅 | 评分 |
|---|---|---|---|---|
| 1 | 科源制药 | 29.89% | 1.63% | 5.1分 |
| 2 | 海翔药业 | 21.69% | -4.98% | 5.0分 |
| 3 | 多瑞医药 | 20.22% | 27.17% | 4.8分 |
| 4 | 新和成 | 18.93% | 10.82% | 6.2分 |
| 5 | 浙江医药 | 17.68% | 2.05% | 6.1分 |
| 6 | 润都股份 | 15.73% | -0.26% | 5.1分 |
| 8 | 联环药业 | 6.82% | 1.86% | 5.4分 |
| 10 | ST人福 | 6.48% | -2.61% | 5.9分 |
| 12 | 广生堂 | 4.76% | -9.20% | 3.8分 |
| 14 | 天新药业 | 2.48% | 1.28% | 5.7分 |
| 16 | *ST三圣 | 1.67% | -0.70% | 4.8分 |
| 18 | 首药控股 | 0.32% | -0.67% | 4.5分 |
| 20 | - | 0.03% | 0.37% | 分 |
| 22 | 兴齐眼药 | -0.24% | 0.92% | 6.1分 |
| 24 | 信立泰 | -0.95% | -6.71% | 4.7分 |
| 26 | 河化股份 | -1.62% | -3.45% | 5.5分 |
| 28 | 哈药股份 | -2.82% | -1.99% | 4.9分 |
| 30 | 西点药业 | -3.16% | -4.13% | 5.4分 |
| 32 | 力生制药 | -3.97% | -1.15% | 5.6分 |
| 34 | 丰原药业 | -4.17% | -4.17% | 5.4分 |
| 36 | 华润双鹤 | -4.63% | -3.08% | 4.8分 |
| 38 | 东亚药业 | -4.94% | -6.84% | 4.8分 |
| 40 | 恩华药业 | -5.23% | -5.39% | 4.7分 |
| 42 | 津药药业 | -5.84% | -5.62% | 5.0分 |
| 44 | - | -5.96% | -6.11% | 分 |
| 46 | 德展健康 | -6.32% | -8.48% | 3.1分 |
| 48 | 川宁生物 | -6.66% | -2.24% | 5.2分 |
| 50 | 科伦药业 | -6.97% | -5.80% | 4.7分 |
| 52 | 恒瑞医药 | -7.38% | -8.43% | 5.1分 |
| 54 | 同和药业 | -7.57% | -7.68% | 4.6分 |
| 56 | 富祥药业 | -7.61% | -8.95% | 4.1分 |
| 58 | 圣诺生物 | -8.01% | -8.19% | 4.9分 |
| 60 | - | -8.12% | -4.04% | 分 |
| 62 | 灵康药业 | -8.32% | -9.09% | 5.1分 |
| 64 | 金陵药业 | -8.46% | -6.91% | 4.8分 |
| 66 | 纳微科技 | -8.51% | -8.86% | 4.5分 |
| 68 | ST复华 | -8.73% | -5.46% | 4.0分 |
| 70 | 莱美药业 | -8.81% | -9.33% | 3.5分 |
| 72 | 新华制药 | -8.95% | -4.78% | 5.0分 |
| 74 | - | -9.14% | -4.42% | 分 |
| 76 | 新天地 | -9.24% | -6.97% | 4.5分 |
| 78 | 华仁药业 | -9.57% | -6.02% | 5.6分 |
| 80 | 共同药业 | -9.60% | -9.68% | 4.1分 |
| 82 | 小方制药 | -9.66% | -6.19% | 4.8分 |
| 84 | 舒泰神 | -9.80% | -9.80% | 4.4分 |
| 86 | 海正药业 | -9.94% | -4.87% | 5.1分 |
| 88 | 尔康制药 | -10.02% | 2.60% | 4.8分 |
| 90 | 罗欣药业 | -10.39% | -9.15% | 4.7分 |
| 92 | 千红制药 | -10.64% | -6.76% | 4.3分 |
| 94 | 华东医药 | -10.70% | -6.44% | 5.1分 |
| 96 | 金城医药 | -10.77% | -5.54% | 4.5分 |
| 98 | - | -11.26% | -5.21% | 分 |
| 100 | - | -11.56% | -4.84% | 分 |
| 102 | - | -11.69% | -5.68% | 分 |
| 104 | 福安药业 | -11.81% | -6.28% | 3.9分 |
| 106 | 富士莱 | -11.96% | -6.29% | 4.7分 |
| 108 | 奥翔药业 | -12.25% | -5.85% | 4.5分 |
| 110 | 哈三联 | -12.43% | -6.89% | 4.0分 |
| 112 | 永安药业 | -12.71% | -6.69% | 4.2分 |
| 114 | 亚太药业 | -12.89% | -7.94% | 4.7分 |
| 116 | 汇宇制药 | -12.97% | -8.60% | 4.5分 |
| 118 | 京新药业 | -13.09% | -7.23% | 4.8分 |
| 120 | - | -13.25% | -7.65% | 分 |
| 122 | ST诺泰 | -13.50% | -1.36% | 4.6分 |
| 124 | 泰恩康 | -13.82% | -10.86% | 3.5分 |
| 126 | 东诚药业 | -14.11% | -9.33% | 4.3分 |
| 128 | *ST赛隆 | -14.71% | -5.59% | 4.2分 |
| 130 | 海思科 | -14.92% | -9.41% | 5.0分 |
| 132 | 拓新药业 | -15.05% | -7.37% | 3.6分 |
| 134 | 盟科药业 | -15.35% | -12.42% | 4.4分 |
| 136 | 康芝药业 | -15.84% | -5.87% | 4.6分 |
| 138 | 鲁抗医药 | -16.57% | -6.41% | 4.3分 |
| 140 | 博瑞医药 | -16.73% | -9.19% | 3.9分 |
| 142 | 一品红 | -17.71% | -9.24% | 4.2分 |
| 144 | 迪哲医药 | -17.85% | -9.37% | 5.0分 |
| 146 | 百济神州 | -19.07% | -17.18% | 4.3分 |
| 148 | 翰宇药业 | -20.66% | -12.51% | 4.5分 |
| 150 | 益方生物 | -22.44% | -8.78% | 4.4分 |
| 152 | *ST景峰 | -24.51% | -11.20% | 4.7分 |
| 154 | 新诺威 | -28.61% | -13.52% | 4.0分 |
| 156 | 悦康药业 | -31.79% | -16.17% | 4.2分 |
行业评级
最近120个交易日，机构评级以增持为主，认为该行业有一定投资价值。
- 综合评级
| 研究机构 | 评级日期 | 最新评级 | 上次评级 |
| 中信证券 | 2012-09-10 | 增持 | 增持 |
| 招商证券 | 2012-09-08 | 增持 | 增持 |
| 航天证券 | 2012-09-06 | 增持 | - |
| 中银国际 | 2012-09-05 | 增持 | - |
| 齐鲁证券 | 2012-09-05 | 增持 | - |
更多>>行业资讯
- 2012-09-13亿利能源股权质押登记
- 2012-09-13太极集团修改《公司章程》
- 2012-09-13人福医药获得国家补助资金
- 2012-09-13常山药业：归还暂时用于补充流动资金的闲置募集资金
- 2012-09-13贵州百灵：公司与济南百诺医药科技开发有限公司签订技
- 2012-09-13振东制药山西省第三建筑工程公司承建山西振东泰盛制药
- 2012-09-13双成药业：战略合作框架协议进展
- 2012-09-13佛慈制药：签订推荐恢复上市、委托代办股份转让协议
- 2012-09-13昊海生科IPO资产被疑是大江股份上市募投项目
- 2012-09-13泰格医药涨势猛 业务有望快速扩张
基本面诊股
[ 截止日期：2025-09-30 ]公司经营
盈利能力：偏弱，与行业平均有较大差距，两项指标的行业排名分别为 120/218 ， 141/218。
[{"date":"2025-09-30","value":"-2.91","vol":"1.51"},{"date":"2025-06-30","value":"-1.88","vol":"1.23"},{"date":"2025-03-31","value":"0.24","vol":"-0.14"},{"date":"2024-12-31","value":"-14.79","vol":"19.62"},{"date":"2024-09-30","value":"0.40","vol":"4.62"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 净资产收 益率(%) |
-2.91 | -1.88 | 0.24 | -14.79 | 0.40 |
| 行业(%) | 1.51 | 1.23 | -0.14 | 19.62 | 4.62 |
该指标值越高，盈利能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"15.91","vol":"49.36"},{"date":"2025-06-30","value":"14.54","vol":"49.33"},{"date":"2025-03-31","value":"23.10","vol":"49.14"},{"date":"2024-12-31","value":"16.10","vol":"50.78"},{"date":"2024-09-30","value":"18.06","vol":"50.61"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 销售毛利 率(%) |
15.91 | 14.54 | 23.10 | 16.10 | 18.06 |
| 行业(%) | 49.36 | 49.33 | 49.14 | 50.78 | 50.61 |
该指标值越高，盈利能力越强，行业排名越靠前。
成长能力：偏弱，与行业平均有较大差距，两项指标的行业排名分别为 117/218 ， 144/218。
[{"date":"2025-09-30","value":"-13.11","vol":"142.98"},{"date":"2025-06-30","value":"-13.42","vol":"79.25"},{"date":"2025-03-31","value":"-12.10","vol":"-0.67"},{"date":"2024-12-31","value":"-26.92","vol":"18.07"},{"date":"2024-09-30","value":"-31.20","vol":"45.94"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 营业收入同 比增长率(%) |
-13.11 | -13.42 | -12.10 | -26.92 | -31.20 |
| 行业(%) | 142.98 | 79.25 | -0.67 | 18.07 | 45.94 |
该指标值越高，成长能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"-714.77","vol":"-3.26"},{"date":"2025-06-30","value":"37.98","vol":"58.57"},{"date":"2025-03-31","value":"106.13","vol":"-11.22"},{"date":"2024-12-31","value":"79.88","vol":"-22.02"},{"date":"2024-09-30","value":"101.88","vol":"-34.66"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 净利润同比 增长率(%) |
-714.77 | 37.98 | 106.13 | 79.88 | 101.88 |
| 行业(%) | -3.26 | 58.57 | -11.22 | -22.02 | -34.66 |
该指标值越高，成长能力越强，行业排名越靠前。
营运能力：一般，低于行业平均，建议投资者谨慎，两项指标的行业排名分别为 130/218 ， 142/218。
[{"date":"2025-09-30","value":"0.15","vol":"0.31"},{"date":"2025-06-30","value":"0.11","vol":"0.21"},{"date":"2025-03-31","value":"0.06","vol":"0.10"},{"date":"2024-12-31","value":"0.23","vol":"0.43"},{"date":"2024-09-30","value":"0.17","vol":"0.33"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 总资产周 转率(次) |
0.15 | 0.11 | 0.06 | 0.23 | 0.17 |
| 行业(次) | 0.31 | 0.21 | 0.10 | 0.43 | 0.33 |
该指标值越高，营运能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"0.42","vol":"1.94"},{"date":"2025-06-30","value":"0.32","vol":"1.30"},{"date":"2025-03-31","value":"0.15","vol":"0.66"},{"date":"2024-12-31","value":"0.57","vol":"3.19"},{"date":"2024-09-30","value":"0.42","vol":"2.12"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 存货增长 率(次) |
0.42 | 0.32 | 0.15 | 0.57 | 0.42 |
| 行业(次) | 1.94 | 1.30 | 0.66 | 3.19 | 2.12 |
该指标值越高，营运能力越强，行业排名越靠前。
现金流能力：数据暂时不全，请后续关注
[{"date":"2025-09-30","value":"-16.27","vol":"4.43"},{"date":"2025-06-30","value":"30.15","vol":"2.74"},{"date":"2025-03-31","value":"39.81","vol":"-26.98"},{"date":"2024-12-31","value":"-38.14","vol":"-373.99"},{"date":"2024-09-30","value":"-23.56","vol":"-9.47"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 现金流量净额/营业收入 | -16.27 | 30.15 | 39.81 | -38.14 | -23.56 |
| 行业 | 4.43 | 2.74 | -26.98 | -373.99 | -9.47 |
该指标值越高，现金流能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"","vol":"0.00"},{"date":"2025-06-30","value":"1.31","vol":"1.73"},{"date":"2025-03-31","value":"","vol":"0.00"},{"date":"2024-12-31","value":"3.21","vol":"2.00"},{"date":"2024-09-30","value":"","vol":"0.00"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 资本支出／折旧和摊销 | - | 1.31 | - | 3.21 | - |
| 行业 | 0.00 | 1.73 | 0.00 | 2.00 | 0.00 |
该指标值越低，现金流能力越强，行业排名越靠前。
短期偿债能力：很强，位居行业前列,建议强烈关注，两项指标的行业排名分别为 87/218 ， 78/218。
[{"date":"2025-09-30","value":"0.87","vol":"3.50"},{"date":"2025-06-30","value":"0.79","vol":"3.69"},{"date":"2025-03-31","value":"0.82","vol":"3.61"},{"date":"2024-12-31","value":"0.91","vol":"3.36"},{"date":"2024-09-30","value":"1.13","vol":"3.67"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 流动比率 |
0.87 | 0.79 | 0.82 | 0.91 | 1.13 |
| 行业 | 3.50 | 3.69 | 3.61 | 3.36 | 3.67 |
该指标值越接近2，短期偿债能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"0.24","vol":"2.75"},{"date":"2025-06-30","value":"0.23","vol":"2.90"},{"date":"2025-03-31","value":"0.25","vol":"2.83"},{"date":"2024-12-31","value":"0.23","vol":"2.65"},{"date":"2024-09-30","value":"0.31","vol":"2.93"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 速动比率 |
0.24 | 0.23 | 0.25 | 0.23 | 0.31 |
| 行业 | 2.75 | 2.90 | 2.83 | 2.65 | 2.93 |
该指标值越接近1，短期偿债能力越强，行业排名越靠前。
长期偿债能力：较强，高于行业平均，建议加强关注，两项指标的行业排名分别为 64/218 ， 8/218。
[{"date":"2025-09-30","value":"68.26","vol":"33.63"},{"date":"2025-06-30","value":"66.97","vol":"33.66"},{"date":"2025-03-31","value":"66.14","vol":"33.90"},{"date":"2024-12-31","value":"66.04","vol":"34.07"},{"date":"2024-09-30","value":"62.19","vol":"32.87"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 资产负债 率(%) |
68.26 | 66.97 | 66.14 | 66.04 | 62.19 |
| 行业(%) | 33.63 | 33.66 | 33.90 | 34.07 | 32.87 |
该指标值越接近50%，长期偿债能力越强，行业排名越靠前。
[{"date":"2025-09-30","value":"2.10","vol":"0.94"},{"date":"2025-06-30","value":"1.98","vol":"0.88"},{"date":"2025-03-31","value":"1.92","vol":"1.47"},{"date":"2024-12-31","value":"1.91","vol":"0.84"},{"date":"2024-09-30","value":"1.60","vol":"0.73"}]
| 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|---|
| 产权比率 (%) |
2.10 | 1.98 | 1.92 | 1.91 | 1.60 |
| 行业(%) | 0.94 | 0.88 | 1.47 | 0.84 | 0.73 |
该指标值越高，长期偿债能力越强，行业排名越靠前。
机构预测
暂时还没有机构预测该股2025年的收益，请投资者后续关注。
[{"date":"2021","yellowRectValue":"2.34","blueLineValue":"","type":""},{"date":"2022","yellowRectValue":"0.18","blueLineValue":"","type":""},{"date":"2023","yellowRectValue":"-12.40","blueLineValue":"","type":""},{"date":"2024","yellowRectValue":"-2.49","blueLineValue":"","type":""},{"date":"2025","yellowRectValue":"0.00","blueLineValue":"","type":"YC"}]